21 August 2024
21 August 2024
Adcendo will acquire ex-China global rights for Multitude’s tissue factor-targeting ADC.
J&J said the drug combination is now the first and only multitargeted, chemotherapy-free combination regimen proven to be superior to Tagrisso.
As obesity rates rise and trust in GLP-1R products grows, sales are forecast to increase four-fold from 2023 to 2030.
Supplies of Emergent’s smallpox vaccine ACAM2000 will accompany Bavarian Nordic’s vaccine to African countries.
Eli Lilly achieved the largest market capitalisation growth of 16.3% over the quarter.
Kainomyx will spearhead the technical strategy and manage the drug discovery and clinical phases.
ReAlta’s pegtarazimod is being developed to treat acute GvHD for patients unresponsive to steroid therapies.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
